Sutro's STRO-004 Shows Early Responses in Phase 1, Cash Runway Extended to Q2 2028
STRO has more than doubled off its 52-week low of $7.15 on light trading volume (0.3× avg).
Summary
Sutro reported Q2 results with $164.3M in cash, extending runway into at least Q2 2028 — a modest decline from $202.6M at Q1 but still solid. The real news is the first clinical data from STRO-004, its TF-targeting ADC: multiple partial responses across pancreatic, head and neck, and NSCLC tumors, with a clean safety profile and low discontinuation rate. Enrollment in the dose-escalation trial moved fast, and the company is now optimizing between 4-5 mg/kg. This is the first efficacy signal for the program and validates the DAR8 exatecan platform. Pipeline momentum continues with STRO-006 on track for Q3 2026 and a second Astellas-partnered dual-payload ADC expected in H2 2026. The data de-risks STRO-004 and could shift sentiment on the broader ADC pipeline.
At the time of this announcement, STRO was trading at $24.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $414.9M. The 52-week trading range was $7.15 to $43.85. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.